Literature DB >> 25192616

Evaluation and management of patients with heart disease and cancer: cardio-oncology.

Joerg Herrmann1, Amir Lerman2, Nicole P Sandhu3, Hector R Villarraga2, Sharon L Mulvagh2, Manish Kohli4.   

Abstract

The care for patients with cancer has advanced greatly over the past decades. A combination of earlier cancer diagnosis and greater use of traditional and new systemic treatments has decreased cancer-related mortality. Effective cancer therapies, however, can result in short- and long-term comorbidities that can decrease the net clinical gain by affecting quality of life and survival. In particular, cardiovascular complications of cancer treatments can have a profound effect on the health of patients with cancer and are more common among those with recognized or unrecognized underlying cardiovascular diseases. A new discipline termed cardio-oncology has thus evolved to address the cardiovascular needs of patients with cancer and optimize their care in a multidisciplinary approach. This review provides a brief introduction and background on this emerging field and then focuses on its practical aspects including cardiovascular risk assessment and prevention before cancer treatment, cardiovascular surveillance and therapy during cancer treatment, and cardiovascular monitoring and management after cancer therapy. The content of this review is based on a literature search of PubMed between January 1, 1960, and February 1, 2014, using the search terms cancer, cardiomyopathy, cardiotoxicity, cardio-oncology, chemotherapy, heart failure, and radiation.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25192616      PMCID: PMC4258909          DOI: 10.1016/j.mayocp.2014.05.013

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  136 in total

1.  Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child.

Authors:  Martin Schweiger; Hitendu Dave; Frithjof Lemme; Anna Cavigelli-Brunner; Olga Romanchenko; Bea Heineking; Michael Hofmann; Chrstoph Bürki; Brian Stiasny; Michael Hübler
Journal:  ASAIO J       Date:  2013 Sep-Oct       Impact factor: 2.872

2.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Authors:  Michael S Ewer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

3.  Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.

Authors:  D Lenihan; T Suter; M Brammer; C Neate; G Ross; J Baselga
Journal:  Ann Oncol       Date:  2011-06-10       Impact factor: 32.976

4.  More 'malignant' than cancer? Five-year survival following a first admission for heart failure.

Authors:  S Stewart; K MacIntyre; D J Hole; S Capewell; J J McMurray
Journal:  Eur J Heart Fail       Date:  2001-06       Impact factor: 15.534

5.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function.

Authors:  F J Giordano; H P Gerber; S P Williams; N VanBruggen; S Bunting; P Ruiz-Lozano; Y Gu; A K Nath; Y Huang; R Hickey; N Dalton; K L Peterson; J Ross; K R Chien; N Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

7.  Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

Authors:  Edith A Perez; Maria Koehler; Julie Byrne; Alaknanda J Preston; Erica Rappold; Michael S Ewer
Journal:  Mayo Clin Proc       Date:  2008-06       Impact factor: 7.616

8.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

9.  Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study.

Authors:  Willis Wu; Ahmad Masri; Zoran B Popovic; Nicholas G Smedira; Bruce W Lytle; Thomas H Marwick; Brian P Griffin; Milind Y Desai
Journal:  Circulation       Date:  2013-04-09       Impact factor: 29.690

10.  Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.

Authors:  Ali Elitok; Fahrettin Oz; Ahmet Y Cizgici; Leyla Kilic; Rumeysa Ciftci; Fatma Sen; Zehra Bugra; Fehmi Mercanoglu; Aytac Oncul; Huseyin Oflaz
Journal:  Cardiol J       Date:  2013-10-21       Impact factor: 2.737

View more
  86 in total

1.  The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.

Authors:  W Law; C Johnson; M Rushton; S Dent
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  Incidence and trends of cardiovascular mortality after common cancers in young adults: Analysis of surveillance, epidemiology and end-results program.

Authors:  Sadeer G Al-Kindi; Guilherme H Oliveira
Journal:  World J Cardiol       Date:  2016-06-26

Review 3.  Guest Editorial: Is Cardio-oncology Ready for Algorithms?

Authors:  Steven M Ewer
Journal:  Eur Cardiol       Date:  2018-08

4.  Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma.

Authors:  Federico Guerra; Marco Marchesini; Daniele Contadini; Alessio Menditto; Marco Morelli; Elisa Piccolo; Nicola Battelli; Mirco Pistelli; Rossana Berardi; Stefano Cascinu; Alessando Capucci
Journal:  Support Care Cancer       Date:  2016-02-29       Impact factor: 3.603

Review 5.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

Authors:  Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

Review 6.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

Review 7.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

Review 8.  Exercise training in cancer related cardiomyopathy.

Authors:  Julian G Westphal; P Christian Schulze
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 9.  Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.

Authors:  Wendy J Bottinor; Christopher K Migliore; Carrie A Lenneman; Marcus F Stoddard
Journal:  Curr Cardiol Rep       Date:  2016-10       Impact factor: 2.931

10.  Nonadherence to Statins and Antihypertensives and Hospitalizations Among Elderly Medicare Beneficiaries With Incident Cancer.

Authors:  Ishveen Chopra; Nilanjana Dwibedi; Malcolm D Mattes; Xi Tan; Patricia Findley; Usha Sambamoorthi
Journal:  J Natl Compr Canc Netw       Date:  2017-11       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.